PISCATAWAY, N.J., Aug. 27, 2024 /PRNewswire/ -- Legend Biotech (LEGN), a subsidiary of GenScript Biotech Corporation (hereinafter referred to as "GenScript"), a global leader in life sciences research ...

R&D Innovation to Lead the Future, Deepening Customer Value Creation From the performance during the 2023 reporting period, GenScript Group's overall development is optimistic, with each business ...

SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corporation ...

PISCATAWAY, N.J., July 9, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that it has been ...

GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction. Legend Biotech continues to invest in R&D to expand the ...

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech, ...

Built upon its solid DNA synthesis technology, GenScript Biotech comprises four major business units: a life-science services and products business unit, a biologics contract development and ...

Detailed price information for Genscript Biotech Corp (GNNSF) from The Globe and Mail including charting and trades.

PISCATAWAY, N.J., April 15, 2024 /PRNewswire/ -- On April 15, GenScript Biotech Corporation ("GenScript"), a world's leading technology and service provider of life science R&D and manufacture, ...

Jefferies analyst Chris Lui maintained a Buy rating on Genscript Biotech (GNNSF – Research Report) on December 21 and set a price target of HK$30.00. The company’s shares closed last Tuesday at $2.65.

In a report released yesterday, Chris Lui from Jefferies maintained a Buy rating on Genscript Biotech (GNNSF – Research Report), with a price target of HK$23.00. Chris Lui has given his Buy rating due ...